Damien Dietrich

Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK

Markus Borner, Dieter Koeberle, Roger von Moos et al. · Annals of Oncology · 2008 · 127 citations · Full text

Swiss Group, Oncology, Gastrointestinal Oncology +10

Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation

Magdalena Waeber, Monica Castiglione‐Gertsch, Damien Dietrich et al. · Annals of Oncology · 2003 · 102 citations · Full text

Surgical Oncology, Breast Oncology, Medicine +10

A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity

Markus Borner, J. Bernhard, Damien Dietrich et al. · Annals of Oncology · 2005 · 102 citations · Full text

Gastrointestinal Oncology, Medicine, Pharmacology +8

Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial)

Sabine Tejpar, Fred T. Bosman, Mauro Delorenzi et al. · Journal of Clinical Oncology · 2009 · 92 citations

Surgical Oncology, Colorectal Surgery, Cancer Management +18

Interleukin-36 potently stimulates human M2 macrophages, Langerhans cells and keratinocytes to produce pro-inflammatory cytokines

Damien Dietrich, Praxedis Martin, Vincent Flacher et al. · Cytokine · 2016 · 82 citations · Full text

Inflammation, Cytokine, Autoimmune Disease +10